Arca
Skip to content
Tools
Tools

Hypochondroplasia

Drug research and approvals for hypochondroplasia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 5 studies of hypochondroplasia are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 0 approved and 2 open orphan designations naming it.

  • Recruiting worldwide: 5
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 5 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

Newest first; search them all in Canada trials
Sep 23, 2026A phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of once-weekly navepegritide versus placebo in…NavepegritideAscendis PharmaPending
Dec 8, 2025Phase 2, open-label, long-term, extension (OLE) study of infigratinib, an fgfr 1-3-selective tyrosine kinase inhibitor, in children with hypochondroplasia:…Infigratinib (BGJ398)Qed Therapeutics, Inc.Ongoing
Jun 13, 2025A phase 3, open-label, long-term extension study to evaluate the safety and efficacy of vosoritide in children with hypochondroplasiaVoxzogo (bmn 111)BioMarin PharmaceuticalOngoing
Mar 26, 2025A phase 2/3, multicenter, open-label phase followed by a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib…InfigratinibQed Therapeutics, Inc.Ongoing
Jul 12, 2024A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia.VosoritideBioMarin PharmaceuticalOngoing

FDA orphan designations

Approved first, then open designations, newest first
Jun 3, 2025InfigratinibTreatment of hypochondroplasiaQED Therapeutics, IncDesignated
Aug 1, 2023VosoritideTreatment of hypochondroplasiaBioMarin Pharmaceutical Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.